New oral agent for lung cancer offers survival benefit

Article

The remarkable advances in the treatment of cancer allow us to use terms like remission and cure, but, regrettably, some of these most effective therapies tend to wipe out the patient along with the disease. And so, researchers scramble to fill the great unmet need of developing the "wonder" drug-one that holds the promise of both efficacy and tolerability. For non-small-cell lung cancer (NSCLC), many have placed their hopes on a new class of agents that inhibit various growth factors. Iressa (gefitinib/AstraZeneca) was the first from the class to be approved, and Tarceva (erlotinib) is the latest.

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Related Content
© 2025 MJH Life Sciences

All rights reserved.